Brett R Hagen
CIK 1681782 · Chief Accounting Officer · last filed 2026-03-23
Brett R Hagen is a Chief Accounting Officer who has filed 49 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing, for KLRS, was dated Mar 23, 2026. Across all open-market trades the lifetime net is −$728.1K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
49
-$728.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRS | Chief Accounting Officer | 0 | $4.33 | $0 | -$21.0K | 3 | 2026-03-23 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Chief Accounting Officer | 2,832 | $9.81 | $27.8K | -$707.1K | 44 | 2025-02-24 |
| KINETA, INC./DE (PTI) Delisted | See Remarks | — | — | — | $0 | 2 | 2017-04-05 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-23 | KLRS | Mixed | −1,915 | -$12.9K | EDGAR |
| 2025-04-11 | KLRS | Grant (A) | — | $0 | EDGAR |
| 2025-03-27 | KLRS | Sell (S) | −907 | -$8.1K | EDGAR |
| 2025-02-24 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −96 | -$967 | EDGAR |
| 2025-01-27 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −36 | -$342 | EDGAR |
| 2025-01-13 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −332 | -$146 | EDGAR |
| 2024-11-20 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −554 | -$304 | EDGAR |
| 2024-11-06 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −1,655 | -$1.4K | EDGAR |
| 2024-10-23 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −965 | -$746 | EDGAR |
| 2024-10-04 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −301 | -$245 | EDGAR |